港股異動 | 諾輝健康-B(6606.HK)漲約4% 獲調入港股通
格隆匯6月7日丨諾輝健康-B(6606.HK)漲約4%,報80港元,高見82.5港元創近三個半月新高,總市值344億港元。深交所發佈關於深港通下的港股通股票名單調整的公吿,諾輝健康獲得調入,今日生效。高盛發表最新報吿表示,諾輝健康競爭對手康立明生物發佈核心產品ColoSafe的最新數據,該公司聲稱PPV(陽性預測值)為66.6%,NPV(陰性預測值)高達99.9%,相對於諾輝健康類似產品為PPV 46.2%及NPV 99.6%。該行認為,上述兩公司的產品是利用不同技術及NMPA 批准的標籤,更指有關康立明生物數據的報道或有誤導成分。該行將諾輝健康目標價由78.18港元上調至89.66港元,維持“買入”評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.